

FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER:
9369 V/vmf

U.S. APPLN. NO. (If known, see 37 CFR 1.5)

09/914239

INTERNATIONAL APPLICATION NO.:
PCT/EP00/01458

INTERNATIONAL FILING DATE:
23 FEBRUARY 2000

PRIORITY DATE CLAIMED:
26 FEBRUARY 1999

TITLE OF INVENTION: MAGE-3 DERIVED IMMUNOGENIC PEPTIDES PRESENTED BY MHC OF CLASS II AND THE USE THEREOF

APPLICANT(S) FOR DO/EO/US: Maria Pia PROTTI and Paolo DELLABONA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau. (see attached copy of PCT/IB/308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Item 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

International Search Report
PCT/IPEA/409
Abstract of the Disclosure on a Separate Sheet
Sequence Listing on Paper and Diskette
Application Data Sheet

U.S. APPLICATION NO. (known) 09/914239

INTERNATIONAL APPLICATION NO.
PCT/EP00/01458

ATTORNEY'S DOCKET NO
9369 V/vmf

CALCULATIONS PTO USE ONLY

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1,000.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	9 - 20 =	0	X \$18.00	\$
Independent claims	2 - 3 =	0	X \$80.00	\$
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270.00	\$

TOTAL OF ABOVE CALCULATIONS =

\$ 990.00

Reduction of 1/2 for filing by small entity, if applicable. Applicant claims Small Entity Status under 37 CFR 1.27. +

SUBTOTAL =

\$ 990.00

Processing fee of \$130 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.49(f)).

TOTAL NATIONAL FEE =

\$ 990.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

TOTAL FEES ENCLOSED =

\$ 990.00

Amount to be
refunded:

charged:

a. ☒ A check in the amount of \$ **990.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. **25-0120** in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required by 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. **25-0120**. A duplicate copy of this sheet is enclosed.

SEND ALL CORRESPONDENCE TO

Customer No. 000466

YOUNG & THOMPSON
745 South 23rd Street
2nd Floor
Arlington, VA 22202

(703) 521-2297 facsimile (703) 685-0573

August 23, 2001

By

Benoit Castel

Benoit Castel
Attorney for Applicants
Registration No. 35,041

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Maria Pia PROTTI et al.

Serial No. (unknown)

Filed herewith

MAGE-3 DERIVED IMMUNOGENIC
PEPTIDES PRESENTED BY MHC OF
CLASS II AND THE USE THEREOF

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to calculation of the filing fee, please
amend the above-identified application as follows:

IN THE CLAIMS:

Amend claim 5 as follows:

--5. (Amended) A composition as claimed in claim
3, for use as a vaccine.--

Maria Pia PROTTI et al.

R E M A R K S

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Respectfully submitted,

YOUNG & THOMPSON

By



Benoît Castel
Attorney for Applicants
Registration No. 35,041
Customer No. 00466
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

August 23, 2001

PTO/PCT Rec'd 04 DEC 2001

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Maria Pia PROTTI et al.

Serial No. 09/914,239
(PCT/EP/00/01458)

BOX PCT

Filed August 23, 2001

MAGE-3 DERIVED IMMUNOGENIC PEPTIDES
PRESENTED BY MHC OF CLASS II AND
THE USE THEREOF

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to the issuance of an action on the merits,
please amend the above-identified application as follows:

IN THE SPECIFICATION:

Replace the paragraph beginning at page 7, line 7, with
the following rewritten paragraph:

--In a preferred embodiment, cells playing an important
role in the induction of the immune response, such as APC,
dendritic cells etc., are genetically engineered with vectors
encoding the peptides of the invention (for example viral or
retroviral vectors, such as those from adenovirus or lentivirus
or MLV). Furthermore, the peptides can also be fused with a
suitable protein carrier, to have a satisfactory processing and
expression at the cell surface. Accordingly, the DNA encoding
for the epitopes of the invention, may be inserted in a suitable

FOI 002 6247660

expression vector, under the control of a suitable viral promoter, such as CMV or SV40, when a very efficient expression is required, or an inducible promoter such as that controlled by ecdysone. The epitopes herein referred correspond to the nucleotide fragments listed in the following Table 1 (SEQ ID NOS 1-11, respectively, as they appear), according to the human MAGE-3 gene sequence deposited at GenBank under the accession number U03735:--.

Replace the heading appearing at page 12, line 1, with the following rewritten heading:

--Table 2: Determination of HLA-DR binding by MAGE-3 derived peptides (SEQ ID NOS 3-5, 7, 10, 1-2, 6, 8-9, 11, respectively, as they appear)--.

IN THE CLAIMS:

Amend claim 1 as follows:

1. (amended) Peptides binding MHC class II molecules selected from the group consisting of (SEQ ID NOS 1-11, respectively, as they appear):

- a) EALGLVGAQAPATEE
- b) RKVAELVHFLLLKYR
- c) GNWQYFFPVIFSKAS
- d) FFPVIFSKASSSLQL
- e) SSLQLVFGIELMEVD

- f) VGFIELMEVDPIGHL
- g) PIGHLYIFATCLGLS
- h) GDNQIMPKAGLLIIV
- i) VQENYLEYRQVPGSD
- j) TSYVKVLHHMVKISG
- k) VLHHMVKISGGPHIS

REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claim 1. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

YOUNG & THOMPSON

By



Robert J. Patch
Attorney for Applicants
Registration No. 17,355
745 South 23rd Street
Arlington, VA 22202
Telephone: 521-2297

December 4, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Paragraph beginning at line 7 of page 7 has been amended as follows:

In a preferred embodiment, cells playing an important role in the induction of the immune response, such as APC, dendritic cells etc., are genetically engineered with vectors encoding the peptides of the invention (for example viral or retroviral vectors, such as those from adenovirus or lentivirus or MLV). Furthermore, the peptides can also be fused with a suitable protein carrier, to have a satisfactory processing and expression at the cell surface. Accordingly, the DNA encoding for the epitopes of the invention, may be inserted in a suitable expression vector, under the control of a suitable viral promoter, such as CMV or SV40, when a very efficient expression is required, or an inducible promoter such as that controlled by ecdysone. The epitopes herein referred correspond to the nucleotide fragments listed in the following Table 1 (SEQ ID NOS 1-11, respectively, as they appear), according to the human MAGE-3 gene sequence deposited at GenBank under the accession number U03735:.

Heading appearing at line 1 of page 12 has been amended as follows:

Table 2: Determination of HLA-DR binding by MAGE-3 derived peptides (SEQ ID NOS 3-5, 7, 10, 1-2, 6, 8-9, 11, respectively, as they appear).

IN THE CLAIMS:

Claim 1 has been amended as follows:

1. (amended) Peptides binding MHC class II molecules selected from the group consisting of (SEQ ID NOS 1-11, respectively, as they appear):

- a) EALGLVGAQAPATEE
- b) RKVAELVHFLLLKYR
- c) GNWQYFFPVIFSKAS
- d) FFPVIFSKASSSLQL
- e) SSLQLVFGIELMEVD
- f) VGFIELMEVDPIGHL
- g) PIGHLYIFATCLGLS
- h) GDNQIMPKAGLLIIV
- i) VQENYLEYRQVPGSD
- j) TSYVKVLHBMVKISG
- k) VLHBMVKISGGPHIS

3/PRTS

09/914239

JC05 Rec'd PCT/PTO 23 AUG 2001
PCT/EP00/01458

WO 00/52045

MAGE-3 DERIVED IMMUNOGENIC PEPTIDES PRESENTED BY MHC OF
CLASS II AND THE USE THEREOF

The present invention relates to peptides derived from MAGE-3 protein and to the use thereof as immunostimulants, specifically as agents capable of stimulating the CD4⁺ T cell immune response.

5 The importance of CD4⁺ T lymphocytes in anti-tumor immunity has been clearly demonstrated in animal models. CD4⁺ T cells exert helper activity for the induction and maintenance of anti-tumor CD8⁺ T cells (Greenberg, P.D., 1991, . Adv. Immunol. 49:281-355; Chen, P., et al., 1993, J. Immunol. 151:244-255; Mandelboim, O., et al., 1995, . Nat. Med. 1:1179-1183; Mayordomo, J.I., et al., 1995, Nat. Med. 1:1297-1302; Bellone, M., et al., 1997, . J. Immunol. 158:783-789; Ostrand-Roseberg, S., et al., 1990, . J. Immunol. 144:4068-4071; James, R., et al., 1991, Immunology, 15 72:213-218), but they may also have an effector function either by indirect mechanism against MHC class II negative tumors, via macrophages activation, or by direct mechanism against MHC class II positive tumors.

Recently, the requirement of cognate CD4⁺ T cell help 20 for optimal induction of anti-tumor CD8⁺ CTL was demonstrated (Ossendorp, F., et al. 1998. J. Exp. Med. 187:693-702). In humans, evidence for a role of CD4⁺ T cells in anti-tumor immunity comes from the study of tumor infiltrating lymphocytes, which revealed the presence of 25 both CD8⁺ and CD4⁺ T cells at the tumor site (Goedegebuure, P.S., et al. 1995. Immunol. Res. 14:119-131; Maccalli, C., et al. 1994. Int. J. Cancer 57:56-62), and from the detection in the sera of neoplastic patients of antibodies directed against tumor antigens (Sahin U. et al., 1997, 30 Curr. Opin. Immunol. 9:709-716). However, in recent years research on the T cell immunity against human tumors has

CONFIRMATION COPY

"62247560" 04021

focused mainly on identification of CD8⁺ HLA class I restricted CTL responses. For example, WO 95/19783 discloses MAGE-3 derived peptides capable of binding to MHC class I molecules, such as the allele HLA-A1. Such peptides
5 usually have a number of residues ranging from 8 to 10 amino acids.

To date tyrosinase, a tissue-specific antigen expressed in normal and neoplastic cells of melanocytic lineage (Topalian, S.L., et al. 1994. Proc. Natl. Acad. Sci. USA 91:9461-9465.; Yee, C., et al. 1996. J. Immunol. 157:4079-4086), is the only melanoma associated antigen demonstrated as a specific target for CD4⁺ melanoma reactive T cells and for which CD4⁺ T cell epitopes have been identified (Topalian, S.L., et al. 1996. J. Exp. Med. 183:1965-1971). WO 97/11669 (Topalian et al.) reports that
10 peptides from this antigen are recognized in association with MHC class II molecules.

Characterization of the CD4⁺ T cell epitope repertoire on other tumor associated antigens, especially those that are tumor-specific and shared among tumors of several histotypes (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693), would contribute decisively to improve the efficacy of peptide-based immunization protocols in neoplastic patients.
20

The family of MAGE genes ("Melanoma Associated Antigen") consists of about 12 members which are expressed in various types of tumors. MAGE-3 is a tumor-specific antigen encoded by a gene expressed in a high proportion of melanomas and in several other tumor histotypes (head and neck squamous cell carcinomas, bladder carcinomas, lung carcinomas and sarcomas) and not in normal tissues, with the exception of testis and placenta (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693). CD8⁺ CTL from melanoma patients recognize HLA class I restricted MAGE-3
25
30

epitopes (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693), and clinical trials with synthetic peptides corresponding to HLA-A1 and/or -A2 MAGE-3 binding sequences are ongoing in patients affected by melanoma and other neoplastic diseases (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693).

According to a first aspect, the invention relates to MAGE-3 derived immunogenic peptides capable of binding to MHC class II molecules. Such peptides have length from 12 to 15 residues and correspond to MAGE-3 fragments (according to the amino acid sequence reported in Gaugler B. et al. 1994, J. Exp. Med. 179, 921-930) 21-35, 111-125, 161-175, 251-265, 286-300, preferably 141-155, 146-160, 156-170, more preferably 171-185, 191-205 and 281-295. The corresponding amino acid sequences are reported in SEQ ID No. 1-11.

The peptides of the invention are characterized by promiscuous binding to different alleles of MHC class II molecules, such characteristic being advantageous in that one same peptide can be recognized by a wider patient population.

In an in vitro binding assay, the peptides of the invention proved capable of binding different purified molecules belonging to widespread HLA-DR alleles, and of inducing activation of CD4⁺ cells. More particularly, it has been observed that stimulation with the peptides of the invention induces a remarkable proliferation of CD4⁺ T cells and of their cytolytic activity. CD4⁺ T cells exposed to such peptides were able to cause lysis of melanoma cells expressing the MAGE-3 protein and the HLA-DR molecules. Details of such experimental evidence are reported in the examples.

The peptides are preferably prepared synthetically, for example according to the procedures described in

Merrifield, (1986) Science 232:341-347, and Barany and Merrifield, The Peptides, Gross and Meienhofer, eds (N.Y., Academic Press), pp. 1-284 (1979). The synthesis can be carried out in solution or in solid phase or with an automatized synthesizer (Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed., Rockford Ill., Pierce Chemical Co. (1984). Alternatively, the recombinant DNA technology can be used, or the peptides can be prepared starting from the natural protein by fragmentation or enzymatic digestion. Furthermore, the amino acid residues can be replaced, preferably conservatively, by other residues of L- or D- amino acids, or added to the disclosed peptides, or they can be chemically modified, for example by amidation of the terminal carboxylic group or by binding with lipophilic groups (e.g. myristyl), or by glycosylation or conjugations with other peptides, to obtain more favourable properties, such as higher affinity to the MHC molecule, higher immunogenicity, better selectivity in inducing the immune response or higher bioavailability after administration. The peptides of the invention can also be chemically derivatized at the side chains which are therefore modified. For example, free carboxylic groups can be derivatized to form salts, methyl- and ethyl- esters or other types of esters or hydrazides.

The peptides of the invention can also be conjugated with known epitopes, for example with epitopes binding HLA molecules of class I, in order to induce a more complete spectrum of responses, of both the cytotoxic and helper type, and to enhance the response against the tumour.

The provision of new epitopes from an antigen not significantly expressed in normal tissues, such as MAGE-3, would allow to prepare vaccines for use in immunotherapy of patients with tumors expressing the same antigen. Furthermore, the CD4⁺ T cells response induced by the

epitopes is strengthened in that those cells, in addition to an intrinsic cytotoxic activity, exhibit also helper activity through the stimulation and proliferation of other T cells, such as CD8⁺T cells, as well as through macrophages activation.

Therefore, according to a further aspect, the invention provides pharmaceutical compositions containing an effective amount of a peptide of the invention, optionally in combination with other known peptides binding MHC class I molecules and corresponding to CD8⁺ T cell epitopes, such as the peptides described in WO95/19783. In addition to the active ingredients, the compositions will contain pharmaceutically acceptable excipients. "Effective amount" herein means a sufficient amount to activate specific lymphocytes and induce an effective response against the tumor. Such an amount will depend on the peptide used, the administration, the severity of the disease to be treated and the general conditions of the patient and will usually range from 1 to 50 µg/ml, for example in case of peptides being loaded on dendritic cells.

According to a preferred embodiment, such compositions will be used for the preventive vaccination of patients with predisposition to neoplasias or in the therapeutical vaccination of neoplastic patients. "Vaccination" herein means both active immunization, i.e. the in vivo administration of the peptides to elicit an in vivo immune response directly in the patient, as in conventional vaccination protocols, for example against pathogens, and passive immunization, i.e. the use of the peptides to activate in vitro anti-tumor CD4⁺ cells, which are subsequently re-inoculated into the patient.

The techniques for the preparation and the use of vaccines are known to those skilled in the art and are

described, per example, in Paul, Fundamental Immunology, Raven Press, New York (1989) or Cryz, S. J., Immunotherapy and Vaccines, VCH Verlagsgesellschaft (1991). Vaccines are conventionally prepared in the form of injectables, suspensions or solutions, but they can also be used in the form of solid preparations or liposomes. The immunogenic ingredients can be mixed with pharmacologically acceptable excipients, such as emulsifiers, buffering agents and adjuvants which increase the efficacy of the vaccine. The latter can be administered according to single or multiple dosage schedule. Multiple dose provides 1 to 10 separate doses, each containing a quantity of antigen varying from 1 μ g to 1000 μ g, followed by further doses at subsequent time intervals, necessary to maintain or to reinforce the immune response and, if required by the subject, a further dose after several months. In any case, the treatment regimen will depend on the response elicited in the treated patient, general conditions and progress of the tumor.

In a further aspect, the invention provides a method for inducing an immune response against tumor cells expressing a MAGE-3 antigen which comprises incubating APC cells (Antigen Presenting Cells) with the peptides of the invention in conditions suitable for the activation of effectors T CD4⁺.

Such conditions comprise loading autologous APC with the peptides and the subsequent exposure to purified T CD4⁺lymphocytes. Suitable APC cells are autologous peripheral blood mononuclear cells (PBMC), dendritic cells, macrophages or activated B cells. The peptides are added to an APC culture for a sufficient time to obtain the peptide/APC binding, and subsequently a cell population containing CD4⁺ CTLs is added, thereby causing activation and proliferation of CTLs. According to a preferred embodiment, T cells are taken from the treated patient and

optionally purified, then, after activation as described above and expansion in suitable culture medium, they are reintroduced in the same patient. Culture media can contain one or more cytokines (such as IL-2 or T-cell Growth Factor) which contribute to the expansion of CD4⁺ precursors.

In a preferred embodiment, cells playing an important role in the induction of the immune response, such as APC, dendritic cells etc., are genetically engineered with vectors encoding the peptides of the invention (for example viral or retroviral vectors, such as those from adenovirus or lentivirus or MLV). Furthermore, the peptides can also be fused with a suitable protein carrier, to have a satisfactory processing and expression at the cell surface. Accordingly, the DNA encoding for the epitopes of the invention, may be inserted in a suitable expression vector, under the control of a suitable viral promoter, such as CMV or SV40, when a very efficient expression is required, or an inducible promoter such as that controlled by ecdysone.. The epitopes herein referred correspond to the nucleotide fragments listed in the following Table 1, according to the (human) MAGE-3 gene sequence deposited at GenBank under the accession number U03735:

TABLE 1

	aa	Amino acid sequence	Nt
	21-35	EALGLVGAQAPATEE	2525-2569
5	111-125	RKVAELVHFLLLKYR	2795-2839
	141-155	GNWQYFFPVIFSKAS	2885-2929
	146-160	FFPVIFSKASSSLQL	2900-2944
	156-170	SSLQLVFGIELMEVD	2930-2974
	161-175	VFGIELMEVDPIGHL	2945-2989
10	171-185	PIGHLIYIFATCLGLS	2975-3019
	191-205	GDNQIMPKAGLLIIV	3035-3079
	251-265	VQENYLEYRQPVGSD	3215-3259
	281-295	TSYVKVLHMHMVKISG	3305-3349
	286-300	VLHMHMVKISGGPHIS	3320-3364
15	The invention also relates to antibodies, fragments or derivatives thereof, directed to the above described peptides. The general methodology for producing antibodies is well known and is disclosed per example in Kohler and Milstein, 1975, Nature 256, 494 or in J.G.R. Hurrel,		
20	Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press Inc., Boca Raton, FL (1982). The antibodies can be polyclonal or, preferably, monoclonal, or antibody fragments like be F(ab') ₂ , Fab, Fv or scFv.		
25	Still a further aspect of the invention is a method for monitoring the frequency and the expansion of specific precursors for the peptides or the complete MAGE-3 protein, in neoplastic patients subject to active vaccination, by the ELISPOT technique (Herr, W. Et al., 1997, J. Immunol. Methods 203:141-52) or by cytofluorimetric analysis using		
30	tetramers consisting of tetrameric soluble molecules avidin-biotin-MHC class II, pulsed with the relevant peptide (Yee, C. et al. 1999, J. Immunol. 162:2227-2234).		

Description of the Figures

Fig. 1: Proliferative activity of CD4⁺ T cells challenged with the MAGE-3 Pool, tested in 2-d microproliferation assays.

5 The data are representative of (n=x) experiments, and are means of triplicate determinations \pm SD. Panel A (n=6): responses to MAGE-3 Pool (0.01, 0.5, 0.1, 0.5, 1 and 5 μ g/ml). Panel B (n=3): responses to recombinant MAGE-3 protein (5, 10 and 20 μ g/ml). Panel C (n=7): responses to
10 the individual synthetic peptides forming the MAGE-3 Pool (10 μ g/ml) at different weeks of propagation. The blank (i.e. the basal level of proliferation of CD4⁺ T cells in the presence of APC only) was subtracted and was as follows: 2 weeks: 30,866 \pm 1,115; 4 weeks: 7,106 \pm 2,201; and 6
15 weeks: 21,838 \pm 2,767. Asterisks indicate responses significantly higher than the blanks (*, P<0.001 and ** P<0.025, as determined by unpaired, one-tailed Student's t test). Panel D (n=5): response to MAGE-3 Pool (5 μ g/ml) (a) and to peptide corresponding to sequence 281-295 (b), in
20 the presence of different doses of L243 mAb (0.25 and 0.5 μ g/ml). The blank was 1,251 \pm 444, the proliferation of CD4⁺ T cells in the presence of MAGE-3 pool was 28,191 \pm 373, and the proliferation in the presence of sequence 281-295 was 22,504 \pm 141.

25 Fig. 2: Cytolytic activity of MAGE-3 specific CD4⁺ T cells.

The data are representative of (n=x) experiments, and are means of triplicate determinations \pm SD. Panel A (n=6):
lytic activity against different HLA-DR matched and unmatched melanoma cells. HLA-DR types of CD4⁺ T cells and
30 melanomas are indicated at the bottom along with their symbols.

Fig. 3: CD4⁺ T cells recognize MAGE-3 (281-295) in association with HLA-DR11 on OI TC cells.

The data are representative of (n=x) experiments, and

are means of triplicate determinations \pm SD. Panel A (n=3): lytic activity of CD4⁺ CTL against LCL alone or LCL pulsed with MAGE-3₁₄₁₋₁₅₄, MAGE-3₁₄₆₋₁₆₀ and MAGE-3₂₈₁₋₂₉₅. Panel B (n=3): cold target inhibition experiments. Cold targets [OI TC (circles) and LCL pulsed with MAGE-3₂₈₁₋₂₉₅ (squares)] were used to inhibit the lytic activity of MAGE-3 specific CD4⁺ CTL against hot OI TC (E/T ratio was 40:1). Percentage of specific lysis against OI TC cells in the absence of cold targets was 26 \pm 1.2%.

For the abbreviations of HLA phenotypes and of cell lines see Example 4.

The following examples illustrate the invention in greater detail.

EXAMPLES

Example 1

DR-Peptide binding assay.

Peptide interactions with detergent-solubilized DR molecules were measured using an ELISA-based high-flux competition assay (Radrizzani, L., et al. 1997. J. Immunol. 159:703-711). HLA-DR molecules were isolated from the following human lymphoblastoid cell lines (LCL): DR1 (DRB1*0101) from HOM-2, DR3 (DRB1*0301) from WT49, DR4 (DRB1*0401) from PREISS, DR5 (DRB1*1101) from SWEIG, DR7 (DRB1*0701) from EKR, and DR8 (DRB1*0801) from BM9. DR2 (DRB1*1501) was isolated from the L cell transfectant L466.1. The molecules were affinity purified using the mAb 1-1C4 (Cammara, G., et al. 1992. Nature 356:799-801), as described in (Sinigaglia, F., et al. 1992. Methods Enzymol. 203:370-386). Peptide competition assay was conducted to measure the ability of unlabeled peptides to compete with a biotinylated indicator peptide for binding to purified DR molecules. The following biotinylated indicator peptides were used: GFKA₇ for DR1 and DR7; GIRA₂YA₄ for DR2; LAYDA₅ for DR3; UD4 for DR4 (Hammer, J., et al. 1995. J. Exp. Med.

181:1847-1855); TT 830-843 for DR5; and GYRA₆L for DR8. The biotinylated indicator peptide and HLA-DR molecules were incubated with 10-fold dilutions (0.001-100 mM) of the unlabeled competitor peptides (peptides corresponding to the MAGE-3 predicted sequences). To determine peptide binding affinity, the promiscuous HA₃₀₇₋₃₁₉ peptide from influenza hemagglutinin (Roche, P.A., et al. 1990. J. Immunol. 144:1849-1856) was included in each competition assay. The relative binding data of the unlabeled competitor peptides were expressed as inhibitory concentration (IC₅₀): i.e. the concentration of competitor peptide required to inhibit 50% of binding of the biotinylated indicator peptide.

The results of the binding assay are reported in the following Table 2.

Table 2: Determination of HLA-DR binding by MAGE-3 derived peptides
HLA-DR alleles

Residues	Sequence	*0101	*0301	*0401	*0701	*0801	*1101	*1501
141-155	GNWQYFFPVIFSKAS	25	>100 (A)	7	0.1	3.2	0.6	3
146-160	FFPVIFSKASSSLQL	10	7	2	0.01	1.5	1.8	0.2
156-170	SSLQLVFGIELMEVD	7	90	45	0.03	7	28	0.18
171-185	PIGHLVIFATCLGLS	0.3	2.8	0.9	0.01	1.5	0.9	0.03
281-295	TSYVKVLHHMVKISG	15	26	70	0.02	0.01	0.03	0.5
21-35	EALGLVGAQAPATEE	14	>100	>100	25	>100	>100	22
111-125	RKVAELVHFLLLKYR	>100	>100	>100	55	7	0.7	0.055
161-175	VFGIELMEVDPIGHL	>100	0.6	28	10	100	>100	100
191-205	GDNQIMPKAGLLIIV	>100	>100	>100	6	1	4	0.07
251-265	VQENYLEYRQVPGSD	>100	>100	>100	26	10	60	5
286-300	VLHHMVKISGGPHIS	15	>100	>100	0.01	14	0.2	0.48

The binding data are expressed as relative binding capability (IC_{50} μM), calculated as concentration of competitor peptide required to inhibit 50% of binding of the biotinylated indicator peptide (indicator peptide). (a) IC_{50} values higher than 100 μM are outside the sensitivity limits of the binding assay.

Example 2Peptide synthesis.

Peptides were synthesized on a 9050 Millipore synthesizer (Millipore Volketswil, Switzerland). The purity of the peptides was evaluated by RP-HPLC and electron spray mass spectrometry. Synthetic peptides were lyophilized and then reconstituted in DMSO at 2 mg/ml concentration and diluted in PBS as needed.

Example 3Propagation of CD4⁺ T cells and proliferation assay.

The synthetic peptides corresponding to the MAGE-3 sequences most promiscuous (141, 155, 146-160, 156-170, 171-185, 281-295) for HLA-DR binding (see Tables 1 and 2) were pooled (MAGE-3 Pool) and used to stimulate the PBMC of an healthy donor whose HLA type, identified by standard serologic typing, is: A1, A2/B41, B52/DR11, as described in Protti, M.P., et al. 1990. J. Immunol. 144:1711-1720. Briefly, 20x10⁶ PBMC were cultivated for 7 days in RPMI 1460 (GIBCO, Grand Island, NY) supplemented with 10% heat inactivated human serum (Technogenetics, Milan, Italy), 2mM l-glutamine, 100 U/ml penicillin, 50 µg/ml streptomycin (Biowhittaker, Walkersville, MD) (TCM) containing the MAGE-3 Pool (1 µg/ml of each peptide). The reactive lymphoblasts were isolated on a Percoll gradient (Protti, M.P., et al. 1990. J. Immunol. 144:1711-1720), further expanded in T cell growth factor (Lymphocult, Biotest Diagnostic Inc., Dreieich, West Germany) and restimulated at weekly intervals with the same amount of antigen plus irradiated (4000 rad) autologous PBMC as APC.

In the proliferation assay CD4⁺ T cells and autologous irradiated PBMC were diluted in TCM to

14

2x10⁵/ml and 2x10⁶/ml, respectively and plated in triplicate in 96 round-bottom well plates (100 μ l of CD4⁺ T cells and 100 μ l of APC). The cells were stimulated with different concentrations of MAGE-3 pool (0.05, 0.1, 0.5, 1 and 5 μ g/ml), each peptide (10 μ g/ml) and different concentrations of rMAGE-3 protein (5, 10 and 20 μ g/ml). Triplicate wells with CD4⁺ T cells alone and APC alone were used as controls. Three wells with CD4⁺ T cells plus APC did not receive any stimulus to determine the basal growth rate (blank). In inhibition experiments different concentrations of mAb L243 or an isotype matched irrelevant mAb (0.25 and 0.5 μ g/ml) were added in triplicate wells of CD4⁺ cells plus APC stimulated with MAGE-3 pool (5 μ g/ml) or MAGE-3₂₈₁₋₂₉₅ (10 μ g/ml). After three days the cultures were pulsed for 16 h with [³H]TdR (1 mCi, well, 6.7 Ci/mol, Amersham Corp., Milan, Italy). The cells were collected with a Skatron Titertek multiple harvester (Skatron Inc., Sterling, VA) and the thymidine incorporated was measured in a liquid scintillation counter.

T cells were 94% CD4⁺ after 1 week of culture and could be propagated in long term culture by weekly restimulation with the MAGE-3 Pool in the presence of autologous irradiated PBMC. In microproliferation assays (Fig. 1) the cells responded vigorously to the MAGE-3 Pool (Panel A), even at low concentrations (100-500 ng/ml). Reactivity to the individual peptides forming the pool was also periodically investigated (Panel C): the CD4⁺ T cells predominantly recognized the peptide corresponding to MAGE-3₂₈₁₋₂₉₅ and, although to a much lower extent, the peptides corresponding to the overlapping sequences MAGE-3₁₄₁₋₁₅₄ and MAGE-3₁₄₆₋₁₆₀.

Reactivity to MAGE-3₂₈₁₋₂₉₅ increased during the propagation of the line (Panel C). The proliferative activity of CD4⁺ T cells in the presence of MAGE-3 Pool (Panel Da) or MAGE-3₂₈₁₋₂₉₅ (Panel Db) was inhibited by addition in culture of different concentrations of L243 mAb (Panel D), demonstrating that the recognition of MAGE-3 sequences was HLA-DR restricted.

The HLA-DR11+ PBMC from the healthy donor were also stimulated with a second pool of synthetic peptides corresponding to the MAGE-3 sequences 21-35, 111-125, 161-175, 191-205, 251-265 and 286-300. The CD4⁺ T cells proliferated in a dose dependent manner to different concentrations of the MAGE-3 pool II, and the study of the epitope repertoire of the MAGE-3 specific CD4⁺ T cells showed recognition of sequences MAGE-3₁₁₁₋₁₂₅, MAGE-3₁₆₁₋₁₇₅ and predominantly MAGE-3₁₉₁₋₂₀₅. Furthermore, MAGE-3 specific CD4⁺ T cells from a melanoma patient, whose HLA-DR type is HLA-DR4/DR11, recognized the sequences MAGE-3₁₄₁₋₁₅₅, MAGE-3₁₄₆₋₁₆₀, MAGE-3₁₅₆₋₁₇₀, MAGE-3₁₇₁₋₁₈₅ and MAGE-3₂₈₁₋₂₉₅. The study of the restriction element showed that all sequences were recognized in association with the HLA-DR4 allele, demonstrating that sequences 141-155, 146-160 and 281-295 are presented to CD4⁺ T cells in association at least with two different alleles (HLA-DR11 and HLA-DR 4).

Example 4

Cytotoxicity assay

CD4⁺ T cells were tested for specific lytic activity in a standard 4-h ⁵¹Cr release assay as described in Protti, M.P., et al. 1996. Cancer Res. 56:1210-1213. The following targets were used: melanoma

cells (SK-Mel 28, HT144, OI TC described in Imro, M.A., et al. 1998. Hum. Gene Ther. 9:1335-1344 and MD TC established in our laboratory from a cutaneous metastasis), and LCL. The HLA-DR type of target cells, identified by molecular or serologic typing, was: SK-Mel 28 (DR*04*13), HT144 (DR*04*07), OI TC (DR*01*11), MD TC (DR*04*11), LCL (DR11). In cold target competition assays, unlabeled target cells (cold targets) were seeded in plates at serial ratios of hot-to-cold target cells. Effector CD4⁺ T cells and ⁵¹Cr-labeled target cells (hot targets) were then added, and cytotoxicity assessed as described above. Percentage inhibition was calculated as follows:

$$[(\% \text{ specific lysis without cold target} - \% \text{ specific lysis with cold target}) / (\% \text{ specific lysis without cold target})] \times 100.$$

CD4⁺ T cells showed cytolytic activity against OI TC and MD TC which express the HLA-DR11 restricting allele, while they did not kill SK-Mel 28 and HT144 which express unrelated HLA-DR alleles (Figure 2a). To verify whether the cytolytic CD4⁺ T cells recognized HLA-DR11 restricted MAGE-3 epitopes on melanoma cells, first was tested their lytic activity against HLA-DR11⁺ LCL unpulsed, or pulsed with the synthetic peptides recognized in microproliferation assays. LCL pulsed with MAGE-3₂₈₁₋₂₉₅ were strongly recognized by the CD4⁺ T cells, while no killing activity against LCL unpulsed or pulsed with MAGE-3₁₄₁₋₁₅₄ and MAGE-3₁₄₆₋₁₆₀ was detectable (Figure 3a). Subsequently, cold target inhibition experiments were performed which showed that the lytic activity of CD4⁺ T cells against OI TC was inhibited by the addition of LCL pulsed with MAGE-3₂₈₁₋

295 (Figure 3b), demonstrating that this sequence is indeed presented by HLA-DR11 on the OI TC melanoma cells. These results further demonstrate that MAGE-3₂₈₁₋₂₉₅ is naturally processed and forms a cytotoxic CD4⁺ T cell epitope.

CD4⁺ T cells specific for sequence MAGE-3₁₉₁₋₂₀₅ also showed cytolytic activity against MAGE-3/HLA-DR11+ melanoma cells and cold/target inhibition experiments showed that the sequence 191-205 was indeed recognized at the surface of the melanoma cells in association with the HLA-DR11 allele and therefore this epitope is naturally processed.

In the case of the patient, the CD4⁺ T cells showed cytolytic activity against the autologous tumor that expresses the MAGE-3 antigen, and against the SK-Mel 28 melanoma cells that express the antigen and the HLA-DR4 restriction allele, while they did not kill melanoma cells expressing the MAGE-3 protein but an unrelated HLA-DR allele.

CLAIMS

1. Peptides binding MHC class II molecules selected from the group consisting of:

- 5 a) EALGLVGAQAPATEE
b) RKVAELVHFLLLKYR
c) GNWQYFFPVIFSKAS
d) FFPVIFSKASSSLQL
e) SSLQLVFGIELMEVD
10 f) VGFIELMEVDPIGHL
g) PIGHLYIFATCLGLS
h) GDNQIMPKAGLLIIV
i) VQENYLEYRQVPGSD
j) TSYVKVLHHMVKISG
15 k) VLHHMVKISGGPHIS

2. Monoclonal or polyclonal antibodies directed to peptides of claim 1.

3. A pharmaceutical composition comprising an effective amount of a peptide of claim 1 together with pharmaceutically acceptable excipients.

4. A composition as claimed in claim 3, further comprising one or more peptides binding MHC class I molecules corresponding to CTL CD8⁺ epitopes.

5. A composition as claimed in claims 3 and 4, for use as a vaccine.

6. A method for inducing an immune response against tumor cells expressing a MAGE-3 antigen, which method comprises contacting APC cells with the peptides of claim 1 in suitable conditions for the activation of effector CD4⁺ T cells.

7. A method as claimed in claim 6, wherein autologous APC are loaded with the peptides and subsequently

contacted with purified CD4⁺ lymphocytes.

8. The use of the peptides of claim 1 for the preparation of an anti-tumor medicament.

5 9. The use as claimed in claim 8, wherein said medicament is a vaccine.

54439 4040
"6224750"

09/914239

JCO5 Rec'd PCT/PTO 23 AUG 2001


ABSTRACT OF THE DISCLOSURE

Peptides derived from the protein MAGE-3, pharmaceutical compositions containing them and the use thereof for inducing an immune response against tumors.

FOR SECRET


1/3

FIG. 1




2/3

FIG. 2



3/3

FIG. 3



SEQUENCE LISTING

<110> FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

<120> MAGE-3 DERIVED IMMUNOGENIC PEPTIDES PRESENTED BY MHC OF
CLASS II AND THE USE THEREOF

<130> SAN RAFFAELE

<140>

<141>

<160> 11

<170> PatentIn Ver. 2.1

<210> 1

<211> 15

<212> PRT

<213> HUMAN

<400> 1

Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala Thr Glu Glu

1

5

10

15

<210> 2

<211> 15

<212> PRT

<213> HUMAN

<400> 2

Arg Lys Val Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg

1

5

10

15

<210> 3

<211> 15

<212> PRT

<213> HUMAN

<400> 3

Gly Asn Trp Gln Tyr Phe Phe Pro Val Ile Phe Ser Lys Ala Ser

1

5

10

15

<210> 4
<211> 15
<212> PRT
<213> HUMAN

<400> 4
Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu Gln Leu
1 5 10 15

<210> 5
<211> 15
<212> PRT
<213> HUMAN

<400> 5
Ser Ser Leu Gln Leu Val Phe Gly Ile Glu Leu Met Glu Val Asp
1 5 10 15

<210> 6
<211> 15
<212> PRT
<213> HUMAN

<400> 6
Val Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His Leu
1 5 10 15

<210> 7
<211> 15
<212> PRT
<213> HUMAN

<400> 7
Pro Ile Gly His Leu Tyr Ile Phe Ala Thr Cys Leu Gly Leu Ser
1 5 10 15

<210> 8
<211> 15
<212> PRT

<213> HUMAN

<400> 8

Gly Asp Asn Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val
1 5 10 15

<210> 9

<211> 15

<212> PRT

<213> HUMAN

<400> 9

Val Gln Glu Asn Tyr Leu Glu Tyr Arg Gln Pro Val Gly Ser Asp
1 5 10 15

<210> 10

<211> 15

<212> PRT

<213> HUMAN

<400> 10

Thr Ser Tyr Val Lys Val Leu His His Met Val Lys Ile Ser Gly
1 5 10 15

<210> 11

<211> 15

<212> PRT

<213> HUMAN

<400> 11

Val Leu His His Met Val Lys Ile Ser Gly Gly Pro His Ile Ser
1 5 10 15

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Mage-3 derived immunogenic peptides presented by MHC of class II and the use thereof

the specification of which: *(check one)*

REGULAR OR DESIGN APPLICATION

- ☐ is attached hereto.
- ☐ was filed on _____ as application Serial No. _____ and was amended on _____ (if applicable).

PCT FILED APPLICATION ENTERING NATIONAL STAGE

- ☒ was described and claimed in International application No. PCT/EP00/01458 filed on 23.02.2000 and as amended on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing (day, month, year)	Priority Claimed
Italy	MI99A000396	26.02.1999	Yes

(Complete this part only if this is a continuing application.)

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status--patented, pending, abandoned)

POWER OF ATTORNEY


The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from _____ as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

As a named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: **Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoît CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,855, and Thomas W. PERKINS, Reg. No. 33,027, c/o YOUNG & THOMPSON, Second Floor, 745 South 23rd Street, Arlington, Virginia 22202.**

Address all telephone calls to Young & Thompson at 703/521-2297.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Maria Pia PROTTI
(given name, family name)

Inventor's signature  Date 10.10.2001

Residence: Milano, Italy ITX Citizenship: Italian

Post Office Address: Via Olgettina 60 - Milano, Italy

Full name of second joint inventor, if any: Paolo DELLABONA
(given name, family name)

Inventor's signature  Date 10.10.2001

Residence: Milano, Italy ITX Citizenship: Italian

Post Office Address: Via Olgettina 60 - Milano, Italy

Full name of third joint inventor, if any:
(given name, family name)

Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Post Office Address: _____